WilmerHale, Securities: Litigation | Chambers USA Profile

About

Provided by WilmerHale

For decades, market participants, corporate clients and individuals have turned to WilmerHale’s experienced lawyers to navigate the complex universe of securities laws and rules of corporate governance actively litigated by government agencies, regulatory bodies and private parties. We have vast experience defending federal and state securities claims alleging fraud, violations of prospectus and other disclosure obligations, breach of fiduciary duty, corporate misconduct, and insider trading, and have helped clients address challenges involving mutual fund trading and marketing, restatements, broker-dealer duties to clients and counter-parties, and regulatory obligations. We are recognized nationally for our defense of major class actions, having secured the early dismissal of countless cases and defeated class certification or obtained summary judgment in many others. Our proven track record includes notable successes in litigation arising from US Securities and Exchange Commission (SEC) enforcement matters and in the resolution of Financial Industry Regulatory Authority (FINRA) arbitration.

To learn more, visit: https://www.wilmerhale.com/en/solutions/securities-litigation

Chambers Review

Provided by Chambers

Securities: Litigation - USA - Nationwide

Band 3

What the Team is Known For

WilmerHale boasts a solid securities litigation practice covering all aspects of the practice area, including securities class action, derivative suits and M&A litigation. It draws upon its outstanding capability in regulatory and white-collar matters to hold an impressive record in cases involving allegations of insider trading, breaches of fiduciary duty and corporate misconduct. The firm frequently represents corporate issuers, with a notable focus on life sciences and technology companies.

Notable practitioners

New York and Boston-based Michael Bongiorno and DC-based Matthew Martens are key contacts in the department.

View ranking table

Work Highlights

WilmerHale represented the directors of Zymergen in a securities class action challenging statements made by the company in connection with its April 2021 IPO.